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Two Sentence Summary:  Bile duct loss during the course of drug induced liver injury is 
uncommon but can be an indication of vanishing bile duct syndrome.  Bile duct loss during 
acute cholestatic hepatitis is an ominous early indicator of possible vanishing bile duct 
syndrome, and the severity of the loss is the best predictor of eventual adverse outcome..  
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Abstract 
Bile duct loss during the course of drug induced liver injury is uncommon but can be an 
indication of vanishing bile duct syndrome. In this work we assess the frequency, causes, 
clinical features and outcomes of cases of drug induced liver injury with histologically proven 
bile duct loss.  All cases of drug induced liver injury enrolled into a prospective database over a 
ten year period that had undergone liver biopsies (n=363) were scored for the presence of bile 
duct loss and assessed for clinical and laboratory features, causes and outcomes.  26 of the 
363 patients (7%) with drug, herbal or dietary supplement associated liver injury had bile duct 
loss on liver biopsy which was moderate to severe (<50% of portal areas with bile ducts) in 14 
and mild (50-75%) in 12.  The presenting clinical features of the 26 cases varied, but the most 
common clinical pattern was a severe cholestatic hepatitis. The implicated agents included 
amoxicillin/clavulanate (n=3), temozolomide (n=3), various herbal products (n=3), azithromycin 
(n=2) and 15 other medications or dietary supplements.  Compared to those without, those with 
bile duct loss were more likely to develop chronic liver injury (94% vs 47%), which was usually 
cholestatic and sometimes severe.  Five patients died and two others underwent liver 
transplantation for progressive cholestasis despite treatment with corticosteroids and ursodiol.  
The most predictive factor of poor outcome was the degree of bile duct loss on liver biopsy.  
Conclusions: Bile duct loss during acute cholestatic hepatitis is an ominous early indicator of 
possible vanishing bile duct syndrome, for which at present there are no known means of 
prevention or therapy. 
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Introduction 
Drug induced liver injury represents a broad array of forms of hepatic injury grouped together 
only because they are all caused by drugs or herbal and dietary supplements (HDS).  The 
clinical patterns vary widely, from an acute hepatitis-like picture, to acute hepatic necrosis, 
cholestatic injury, fatty liver disease, sinusoidal obstruction syndrome, nodular regenerative 
hyperplasia and cirrhosis.  Some of the variation relates to the mode of cellular injury (necrosis, 
apoptosis, mitochondrial damage), but some relates to the liver cell type that bears the brunt of 
injury: whether hepatocytes, cholangiocytes, sinusoidal lining cells or venular endothelial cells.  
In this regard, the common forms of cholestatic liver injury from medications might reflect injury 
first and foremost to mature cholangiocytes or biliary epithelium or their progenitor cells.  
Although liver biopsies taken during acute drug induced liver injury not infrequently show injury 
to bile ducts, they rarely demonstrate loss of bile ducts despite prominent cholestasis and 
inflammation.  The exception to this generalization is the vanishing bile duct syndrome (VBDS), 
a rare but serious complication of some cases of cholestatic drug injury to the liver.1-12   
Vanishing bile duct syndrome is an uncommon but potentially severe form of chronic liver 
disease.  Known causes of VBDS include graft-vs-host disease, primary biliary cirrhosis, 
sclerosing cholangitis, paraneoplastic syndromes, Alagille syndrome and drugs.  Rarely, VBDS 
arises without a known cause and can be referred to as idiopathic.  The full spectrum of VBDS, 
particularly that due to medications, is not well known.  VBDS has been described largely in 
isolated case reports or small case series that generally represent the most severe and 
dramatic examples of this injury.  The frequency of bile duct loss during drug induced liver injury 
and its overall course and outcome, particularly whether it invariably leads to VBDS, have not 
been well characterized.  In a large, long-term prospective study of drug induced liver injury in 
the United States, we have assessed the frequency, causes, clinical patterns and outcomes of 
cases in which liver biopsies demonstrated appreciable bile duct loss.  
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Materials and Methods 
The Drug Induced Liver Injury Network (DILIN) is a prospective, collaborative study of drug-
induced liver injury in the United States, which was initiated in 2003 as a cooperative agreement 
funded by the National Institutes of Health (NIH)13,14  Additional details are in Supplementary 
Material. 
After 6 months of follow up, cases were adjudicated for the likelihood that the injury was due to 
the implicated drugs or HDS by a causality committee.15   All cases were scored as being 
definite (1: ≥95% likelihood), highly likely (2: 75-94%), probable (3: 50-74%), possible (4: 25-
49%) or unlikely (5: <25%).  For cases with more than one implicated agent, each drug or HDS 
was scored separately in a similar manner.  For the purposes of this analysis, only cases scored 
as probable, highly likely or definite were used.14  All cases were also graded for severity on a 
scale of 1 to 5 as mild, moderate, moderate and hospitalized, severe or fatal using standardized 
criteria.13   For the current analyses, chronicity was scored for both severity and biochemical 
pattern at 6, 12 and 24 months and at the last visit as none (0: serum ALT, Alk P in reference 
ranges, total bilirubin ≤1.2 mg/dL and INR < 1.5 or missing); mild (1: ALT 1 to 3 times and/or Alk 
P 1 to 2 times ULN and/or bilirubin >1.2  mg/dL but <2.5 mg/dL, and INR < 1.5 or missing); 
moderate (2: ALT > 3 times or Alk P > 2 times ULN but bilirubin < 2.5 mg/dL and INR < 1.5 or 
missing); moderately severe (3: ALT or Alk P elevated above ULN,  serum bilirubin ≥ 2.5 mg/dL 
and INR <1.5); or severe (4: ALT or Alk P elevated above ULN,  bilirubin ≥ 2.5 mg/dL with INR ≥ 
1.5 or other signs of liver failure) (Supplementary Table 2).  The pattern of persistent injury 
was characterized as cholestatic, mixed or hepatocellular based upon R ratio, where R = (ALT 
value/ALT ULN) divided by (Alk P value/Alk P ULN).  By usual convention values of R< 2 are 
defined as cholestatic, R> 5 as hepatocellular and R=2-5 as ‘mixed’.13   
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All deaths and liver transplants recorded in the DILIN Prospective study were assessed by 
committee in a standardized manner, and the role of the drug- or HDS- induced liver injury was 
scored as the primary cause, a contributory cause or not related.17 
A liver biopsy was not required as a part of the DILIN Prospective Protocol, but if performed in 
the course of routine medical care, a request was made that de-identified, recut, unstained 
slides be prepared and sent to the Laboratory of Pathology, National Cancer Institute, in the NIH 
Clinical Center (Bethesda, MD). Biopsies were read by the DILIN hepatic pathologist (D.E.K.) 
without specific clinical information and scored for multiple findings.16  In this system, bile duct 
paucity was scored as 0 (none or normal: > 75% of portal areas had bile ducts), 1+ (mild loss: 
50-75% of portal areas had bile ducts) or 2+ (moderate-to-severe loss: <50% of portal areas 
had bile ducts).  Cases were also analyzed for the number of portal areas and the number with 
identifiable bile ducts, which allowed calculation of the fraction of portal areas with bile ducts.  
Results are presented as median values and ranges.  Statistical significance among groups was 
determined by Wilcoxon rank-sum test for continuous variables, Fisher’s exact test for binary 
variables, Chi-Square for categorical variables and log-rank tests for time-to-event variables.  
The statistical analyses were done using SAS 9.4 (SAS Institute, Cary, NC), and p values of 
<0.05 were considered significant.   
 
Results  
Cohort of patients with bile duct loss:  Over a ten year period (September 2004 to 
September 2014), 1433 subjects with suspected drug induced liver injury were enrolled in the 
DILIN Prospective Protocol, among whom 1296 completed 6 months of follow up data accrual 
and underwent central adjudication of causality.  Among the adjudicated cases, 1056 (81.5%) 
were judged to be probable, highly likely or definite drug-induced liver injury, and, among these, 
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363 (34%) had liver biopsies that were available and deemed adequate for histopathological 
interpretation.  Among these 363 cases, 26 (7%) had evidence of bile duct loss, which was 
scored as mild in 12 and moderate-to-severe in 14.  The process of development of two cohorts 
(with and without bile duct loss) is shown in Figure 1. 
Clinical features of cohort:  The demographic, clinical, laboratory and histologic features of the 
26 cases with bile duct loss are summarized in Table 1.  The median age was 53 years (range 
11 to 87), all except one were adults, and 54% were women.  All except one (96%) were 
jaundiced (serum total bilirubin > 2.5 mg/dL).  Other common symptoms included itching (77%), 
nausea (46%), fatigue (42%) and abdominal pain (42%).  The time to onset after starting the 
implicated medication ranged from 3 to 551 days with a median of 38 days.  The laboratory 
results at onset were typically cholestatic with prominent elevations in Alk P (median and range: 
368; 71 to 1261 U/L) and mild to moderate increases in ALT levels (296; 57 to 1268 U/L).  The 
median R ratio was 1.7 but ranged from 0.6 to 8.0; the R ratio being in the low range for 
hepatocellular injury in 5 cases (19%: 6.3 to 8.0), in the mixed range in 6 (23%: 2.4 to 3.7) and 
cholestatic range in 15 (58%: <2.0).  Rash was reported in 10 patients (39%), fever in 12 (46%) 
but peripheral eosinophilia in only 4 (15%).  Among the 10 patients with rash, half were 
diagnosed with a severe cutaneous reaction: two with drug reaction with eosinophilia and 
systemic signs (DRESS syndrome) and one each for Stevens Johnson syndrome, toxic 
epidermal necrolysis and erythema multiforme.   
Comparison of patients with and without bile duct loss:  Table 1 also provides a 
comparison of the 26 cases with and the 337 cases without bile duct loss on liver biopsy.  The 
two groups were similar in age, sex and race, but those with bile duct loss were more likely to 
have jaundice and a cholestatic pattern of liver enzyme elevations (R <2.0 in 57% vs 23%) .  
Cases with duct loss were also more likely to have rash and fever than the control group.  
Overall, the peak bilirubin and initial and peak Alk P levels were higher in the bile duct loss 
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group, while initial and peak ALT levels were lower.  Importantly, the mortality rate was higher in 
those with bile duct loss vs those without (27% vs 9%, p = 0.01) as was the rate of chronicity 
among patients followed for at least 6 months (94% vs 47%, p < 0.001). 
We also compared the 26 cases with bile duct loss to all those with R values ≤ 8 who underwent 
liver biopsies.  These control subjects have clinical features and types of liver injury that more 
closely resemble those of the study cohort.  The results are summarized in Suppl Table 3. 
Differences in those with bile duct loss include a trend for greater frequency of African 
Americans [6/26 (23%) vs 20/193 (10%), p= 0.097, Fisher’s exact test, 2 sided], higher levels of 
serum Alk P and total bilirubin, significantly higher INR, higher scores for severity at baseline, 
and much greater risk of chronicity and likelihood of poor outcomes.   
 
Drugs implicated in causing bile duct loss: Adjudication of the causality identified 2 cases as 
definite, 14 highly likely and 10 probable.  However, many patients had taken multiple 
medications within two months of onset, and the specific agent that caused the liver injury was 
not always clearly defined.  The various agents that were implicated in the 26 cases of drug-
induced liver injury with bile duct loss are listed in Table 2, which also shows the numbers of 
cases attributed to these agents among all 363 patients who underwent liver biopsy.  The most 
commonly associated agents in the cohort with bile duct loss included amoxicillin-clavulanic 
acid, HDS products, azithromycin and the fluoroquinolones, but these were also commonly 
associated agents in the control population of cases.  In the biopsy cohort, 3 of the 4 
temozolomide cases demonstrated bile duct loss.  Similarly, the only cases of liver injury 
attributed to several other agents in this cohort represented cases in the bile duct loss group, in 
particular thalidomide and its derivative, lenalidomide.  In many cases, however, the implicated 
agent was considered only “probable” or “possible” and there were other possibly implicated 
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agents.  Indeed, for the cohort with bile duct loss, the mean number of other medications being 
taken within two months of onset of liver injury was 9.6 , the median was 7.5, and the range was 
1 to 35.  Similarly, among the 337 subjects who underwent liver biopsies that did not show bile 
duct loss, the mean number of concomitant drugs was 6.9, the median was 5, and the range 
was 1-51. Differences between the two groups were not significant [p=0.09].  Among the other 
agents taken within two months of onset were several drugs that have been linked to VBDS12 , 
including cephalosporins (n=8), fluoroquinolones (n=2), azithromycin (n=4), erythromycin (n=1), 
clindamycin (n=2), amoxicillin (n=1), carbamazepine (n=1), lamotrigine (n=1), ibuprofen (n=2), 
acetaminophen (n=6), omeprazole (n=10), lansoprazole (n=2), atorvastatin (n=4), fenofibrate 
(n=1) and metoclopramide (n=1). 
Frequently implicated agents among cases that underwent liver biopsy but did not show bile 
duct loss included drugs associated with purely hepatocellular injury such as nitrofurantoin, 
isoniazid and minocycline.  Important causes of cholestatic liver injury that were not linked to 
any cases of duct loss included the anabolic steroids and estrogens.  Thus, among 16 cases of 
anabolic steroid associated jaundice who underwent liver biopsies and were enrolled in the 
DILIN database, none demonstrated significant bile duct loss.   
Histopathological findings [Figure 2]:  Histopathological changes were diverse.  Usually, 
inflammatory infiltrates were mild, with little or no direct interaction with the remaining ducts. 
Residual ducts showed reactive epithelial changes consistent with injury or repair.  Chronic 
cholestatic changes were common with periportal pseudoxanthomatous changes of 
hepatocytes, copper accumulation and, sometimes, marked ductular reaction.  Sclerosing duct 
changes reminiscent of sclerosing cholangitis were seen in a few ducts in four of the 26 cases. 
Acute large duct obstruction can cause zone 3 cholestasis but would not cause duct loss.  
Chronic large duct obstruction could be considered in some cases, but would also not cause 
duct loss and, furthermore, had been excluded by imaging. 
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Outcomes of cases with bile duct loss:  Outcomes of the liver injury among the 26 cases with 
bile duct loss are shown in Table 3.  By the time of the 6 month follow up visit, 5 patients had 
died and 5 others had been lost to follow up.  Of the 16 patients with 6 months of follow up, 15 
(94%) had biochemical evidence of persistent injury, which was cholestatic in all 15 adults 
(median R ratio = 0.8) and mixed in the one adolescent in the cohort (R = 3.4). The persistent 
injury at 6 months was scored as severe in 1 (evidence of hepatic failure), moderately severe in 
3 (serum total bilirubin >2.5 mg/dL), moderate in 9 (Alk P > twice ULN) and mild in two.  One 
year follow up was available on 13 and two year on 9 of those with persistent injury at 6 months, 
all except two of whom continued to have biochemical evidence of cholestatic liver injury.  With 
time, median values of Alk P and bilirubin decreased and median chronicity score declined from 
2.0 at 6 months to 2.0 at one year and 1.0 at two years.  Among the original 26 patients with bile 
duct loss, 7 died and 2 underwent liver transplantation.  Among those who died, the liver injury 
was scored as the primary cause in 2, a contributory cause in 3 and unrelated in 2 cases.   
Early liver biopsies showing bile duct loss:  In 19 patients, the liver biopsy demonstrating 
bile duct loss was done within 3 months of onset; the remaining 7 being done 7 to 22 months 
later.  Indeed, 6 patients with bile duct loss on a late biopsy had had initial biopsies within 3 
months of onset that did not show significant duct loss.  These 6 patients did not differ in clinical, 
biochemical features or even in other histologic features from those who had duct loss on early 
biopsy.  However, the early biopsies not showing bile duct injury had fewer numbers of portal 
areas (median 7, range 4 to 9) than the biopsies that did show bile duct loss (median 14, range 
7 to 28) (p = 0.002), suggesting that the early biopsies in these 6 patients may have been sub-
optimal for reliable assessment of duct loss (Suppl Table 4). 
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Among the 19 patients with early liver biopsies showing bile duct loss, 9 were scored as mild, 5 
of whom had 6 months of follow up, at which time 4 had evidence of persistent cholestatic liver 
injury.  In further follow up, none of these patients underwent liver transplantation or died of 
progressive liver disease (two died of brain cancer unrelated to the drug reaction).  Among the 
10 patients with early liver biopsies showing moderate-to-severe bile duct loss, 6 month follow 
up was available in 8, of whom 4 died.  The liver injury was considered the primary cause of 
death in 2 and contributory in 2.  The remaining 4 patients all had persistent cholestatic liver 
injury that was scored as moderate or severe at 6 months and was still moderate or severe 
when they were last seen, one undergoing liver transplantation at 22 months after onset and 
one dying with liver injury considered a contributory cause.   
Predictive factors for poor outcome: Analysis of predictive factors for a poor outcome was 
done limiting the analysis to the 20 patients with at least 6 months of follow up or death before 6 
months.  A poor outcome was considered one of the following: (1) death in which the liver injury 
was considered th  primary (n=2) or a contributory (n=3) cause, (2) liver transplantation (n=2), 
or (3) persistent liver injury, which on final assessment was still moderate or severe (chronicity 
severity score 2, 3 or 4: n=7).  Using these criteria, 13 patients were considered to have poor 
and 7 benign outcomes.  The demographic, clinical, biochemical and histologic features of the 
two groups are compared in Table 4.  As shown, the benign vs poor outcomes groups tended to 
differ somewhat in median age (63.5 vs 48.2 years, p = 0.08) and race (14% vs 38% African 
American, p = 0.35) but not in regard to sex, duration of drug use to onset, or treatment with 
corticosteroids or ursodiol.  Laboratory test results at the onset of injury were similar in those 
with a benign vs poor outcome, but by the time of liver biopsy, those with a poor outcome had 
more abnormal laboratory test results.  Histologic features of disease activity (HAI scores), 
fibrosis, copper accumulation, and evidence of bile duct injury were similar in those with benign 
and poor outcomes.  The factor most closely related to poor outcome was the degree of bile 
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duct loss on liver biopsy:  those with moderately severe to severe bile duct loss being invariably 
associated with a poor outcome.  All biopsies were re-reviewed by the hepatopathologist and 
the number of adequately sized portal tracts and number of those with an identifiable bile duct 
were counted.  The average percent of portal areas with bile ducts in those with a benign 
outcome was 64% compared to only 17% in those with a poor outcome (p = 0.003). 
Selected representative case summaries are given in the Supplemental Material, including 
patients with bile duct loss with subsequent progressive cholestasis resulting in death (Case 1) 
or liver transplantation (Case 2); severe acute cholestasis with residual injury 2 to 3 years after 
onset (Cases 3, 4 and 5); and marked acute cholestasis with complete resolution by 6 months 
(Case 6) or after several years (Case 7). 
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Discussion 
In this cohort, 26 of 363 (7%) cases of drug-induced liver injury undergoing liver biopsy had 
histologic evidence of bile duct loss.  Analysis of the characteristics of those with bile duct loss 
demonstrated that they typically had a moderate-to-severe acute cholestatic liver injury with 
immunoallergic features, some patients having severe cutaneous reactions such as DRESS, 
Stevens Johnson syndrome or toxic epidermal necrolysis.  Importantly, the histologic finding of 
bile duct loss was associated with evolution to chronic liver injury (94%) and a high liver-related 
morbidity and mortality (26%).  The major causes of VBDS in this cohort included many of the 
common causes of cholestatic hepatitis such as amoxicillin/clavulanate 4-6, 18, azithromycin 8,19 
and fluoroquinolones 4,9, 20.  Isolated cases were due to allopurinol, thalidomide, lenalidomide, 
montelukast and cephalosporins.  Single cases were due to agents that are very rare causes of 
liver injury such as omeprazole, lansoprazole and enalapril.  In some it was difficult to 
confidently attribute the injury to one specific agent.  Strikingly, many common causes of drug-
induced liver injury were not linked to any of these bile duct loss cases, examples including 
isoniazid, minocycline, nitrofurantoin, diclofenac or common causes of “bland cholestasis” such 
as estrogens and anabolic steroids.  A special exception to the rarity of bile duct injury was 
temozolomide, a relatively recently introduced alkylating agent that crosses the blood-brain 
barrier and is used extensively in the treatment of malignant brain tumors. 21, 22 
In this case series, 2 of the 26 patients with bile duct injury on liver biopsy ultimately died with 
severe, progressive cholestatic liver injury and 2 others underwent liver transplantation with a 
similar clinical syndrome suggestive of VBDS.  Three other patients died and the cholestatic 
liver injury was considered contributory.  Thus, the overall mortality of acute drug induced liver 
injury with bile duct loss may be as high as 27%.  In one instance of liver transplantation in this 
cohort, complete absence of bile ducts was documented in the explanted liver.  In the other 
cases VBDS was assumed to be the cause of the progressive injury. 
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While the mortality rate of liver injury with bile duct loss was high, some patients recovered 
clinically and a few resolved all biochemical evidence of liver injury or cholestasis.  Thus, in 
follow up, 2 of 26 patients (11%) with bile duct injury and paucity initially (both with mild duct 
loss on biopsy) had complete resolution with no symptoms and normal liver tests when seen 6 
months after onset.  Another 8 patients (31%) had mild to moderate alkaline phosphatase 
abnormalities but had no symptoms or bilirubin elevations, suggesting residual, subclinical bile 
duct loss that might be considered mild or a form fruste of VBDS.  The best predictor of a 
benign vs poor outcome in this study was the degree of bile duct loss. There was a trend for 
poor outcomes to be associated with younger age at onset and African-American race.  The 
numbers of cases in this series was not sufficient to perform multivariate analyses of these 
factors, but certainly the roles of age and race in influencing the course and outcome of drug-
induced liver injury are important topics for further investigation.  A high proportion of patients 
were treated with corticosteroids and ursodiol (Table 4), but with little evidence of effect in 
individual cases or overall.   
The pathogenesis of bile duct loss and VBDS is not known, but it is clearly idiosyncratic and 
likely to be due to immunologically mediated injury to bile ducts.  Supportive of this concept is 
that the major causes of idiosyncratic cholestatic hepatitis are common causes of VBDS, 
whereas the major causes of acute hepatocellular injury (and acute liver failure) are uncommon 
causes of VBDS.  The association of the most severe cases of VBDS with severe cutaneous 
reactions such as Stevens Johnson syndrome suggests that VBDS may be due to an aberrant 
hypersensitivity reaction affecting cholangiocytes in addition to keratinocytes, perhaps because 
of shared immunogenic proteins or shared ability to present drug-protein-adducts or 
immunogenic drug metabolites on their cell surface.   
Strengths of this study include the number of cases of suspected VBDS, the availability of liver 
histology from early in the course of injury, the standardized fashion of evaluation, causality 
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assessment, grading and staging and the central “blinded” histologic readings.  This series also 
represents the full spectrum of this form of liver injury, including mild cases that resolve and 
severe cases that lead to death or liver transplantation.  Another strength is that all cases of 
suspected drug-induced liver injury were enrolled and not just classic and clear cut instances.  
The complexity of many cases and the multitude of drugs to which they were exposed might 
appear to be a weakness in this study, but actually represents a more unbiased representative 
sample of what occurs in clinical practice.   
Weaknesses of the study must also be considered.  Not all patients enrolled in DILIN undergo 
liver biopsies, and the decision to perform biopsies is made locally based upon clinical judgment 
and not as a part of a standardized protocol.  In support of the potential for selection bias in the 
patients undergoing liver biopsies, the overall incidence of chronic liver injury (49%) was 
substantially higher in this subgroup of patients compared to the 17% rate we previously 
reported in 899 consecutively enrolled patients.  This difference was likely due to the selection 
of patients with non-resolving laboratory abnormalities to undergo liver biopsies (14).  In addition, 
many other cases of bile duct loss and vanishing bile duct syndrome may have been enrolled in 
the DILIN database, but without liver biopsies such cases could not be included in this series.  
Furthermore, the liver biopsies subjected to central review were recuts of the original 
specimens, and one reason for some patients not having identifiable bile duct loss on early 
biopsies may have been the limited size of the recut sample.  Indeed, these data suggest that a 
minimum of ten portal tracts is needed to reliably exclude significant bile duct loss and 
possibility of ultimately developing vanishing bile duct syndrome.  Another limitation of the study 
is that, despite assiduous efforts, follow-up of subjects was incomplete. 
In summary, the finding of bile duct loss on liver biopsy during an acute liver injury has a poor 
prognosis, especially if the bile duct loss is moderate or severe (i.e. fewer than 50% of portal 
areas with an identifiable bile duct).  The assessment requires an adequate biopsy specimen 
Page 18 of 76
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
Bonkovsky et al. HEP 16-1690R1.cc. Bile Duct Loss due to Drugs.   19 
and careful enumeration of the number of portal tracts and the number without identifiable bile 
ducts.  Many drugs are capable of causing bile duct loss and vanishing bile duct syndrome, but 
predominantly those that cause acute cholestatic or mixed hepatitis with immunoallergic 
features.  Although not formally studied in this work, therapies, including corticosteroids and 
ursodiol do not appear to have major salutary effects on the course and outcome of bile duct 
injury. Other approaches to diagnosis and management of this potentially severe complication 
of cholestatic drug-induced liver injury are needed. 
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Table 1:  Selected Features of Subjects with Bile Duct Loss Compared to Biopsied 
Subjects without Duct Loss 
Feature Bile Duct Loss 
(n=26) 
No Duct Loss 
(n=337) 
     P values 
Sex (Female) 14 (54%) 201 (60%) 0.68 
Race   0.16 
           White 
           Black 
           Other 
20 (77%) 
6 (23%) 
0 
266 (79%) 
45 (13%) 
26 (8%) 
 
 
Age* (years) 53 (11-87) 50 (8-86) 0.12 
Symptoms (any) 25 (96%) 317 (94%) 1.00 
      Jaundice 25 (96%) 263 (78%) 0.02 
      Itching 20 (77%) 198 (59%) 0.10 
      Fatigue 11 (42%) 179 (53%) 0.31 
      Abdominal Pain 11 (42%) 154 (46%) 0.84 
      Rash 10 (39%) 87 (26%) 0.17 
      Fever 12 (46%) 84 (25%) 0.04 
Eosinophils >500/µL 4 (15%) 43/326 (13%) 0.76 
ANA--positive 5 (19%) 98/328 (30%) 0.37 
SMA--positive 4/25 (16%) 77/319 (24%) 0.47 
Latency* (days) 38 (3-551) 58 (1-7046) 0.05 
Initial:  Bilirubin* (mg/dL) 7.2 (0.2-34.1) 5.9 (0.2-32.5) 0.49 
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               ALT* (U/L) 296 (57-1,268) 543 (6-10,000) 0.01 
               Alk P* (U/L) 368 (71-1,261) 215 (41-1,952) <0.001 
               R ratio* 1.7 (0.6-8.0) 6.4 (0.1-100) <0.001 
Peak: Bilirubin* (mg/dL) 21.5 (0.6-59) 13.9 (0.3-55) <0.01 
            ALT* (U/L) 497 (97-3,388) 713 (9-10,000) 0.17 
            Alk P* (U/L) 804 (357-2,414) 297 (65-2,865) <0.001 
            INR* 1.6 (1.0-6.8) 1.2 (0.9-13.1) 0.11 
Bilirubin peak to <2.5 
mg/dL, median in days 
70 (n=23) 34 (n=274) <0.01 
Corticosteroid therapy  20 (77%) 142/328 (43%) <0.01 
Ursodiol therapy 16 (62%) 88/328 (27%) <0.001 
Severity Score * 3.5 (1-5) 3.0 (1-5) 0.04 
Severity Score:   
       1 (mild) 
       2 or 3 (moderate) 
       4 or 5 (severe or fatal)       
 
1 (4%) 
12 (46%) 
13 (50%) 
 
57 (17%) 
168 (50%) 
114 (34%) 
0.04 
 
 
Chronicity at 6 months 15/16 (94%) 98/209 (47%) <0.001 
Liver Transplantation ‡ 2 (8%) 24 (7%) 0.71 
Death, all causes ‡ 7 (27%) 30 (9%) 0.01 
           Primary   2 (8%) 14 (4%)  
           Contributory 3 (12%) 7 (2%)  
           Unrelated 2 (8%) 9 (3%)  
 
• = Median (range); ‡ = at any time point within 2 years of onset 
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Table 2:  Agents Associated with Bile Duct Loss 
Agent Bile Duct Loss 
(n = 26) 
Total Biopsied 
(n=363) 
Amoxicillin-Clavulanate 3 (11%) 34 (9%) 
HDS products* 3 (11%) 18 (5%) 
Temozolomide 3 (11%) 4 (1%) 
Azithromycin 2 (8%) 10 (3%) 
Fluoroquinolones 2 (8%) 13 (4%) 
Lenalidomide/Thalidomide 2 (8%) 2 (<1%) 
Allopurinol 1 4 (1%) 
Cefalexin 1 1 
Cefazolin 1 11 (3%) 
Enalapril 1 1 
Infliximab 1 1 
Lansoprazole 1 1 
Mesalamine 1 1 
Metoclopramide 1 1 
Montelukast 1 1 
Olanzapine 1 1 
Omeprazole 1 1 
*The names of the botanical /herbal agents were as follows:  Artemisia annua, 500 mg 
capsules; Gluco-Ease Plus, Proprietary blend, 525, mg capsules; traditional Chinese medicine, 
incriminated in the third case due to HDS could not be ascertained. 
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Agents most frequently implicated in cases without bile duct loss, which are not in the list above, 
include nitrofurantoin (n=21), anabolic steroids (n=16), minocycline (n=14), isoniazid (n=8) and 
trimethoprim/sulfamethoxazole (n=8).  
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• Table 3:  Liver Test Abnormalities and Chronicity Severity Scores in 26 Patients 
with Bile Duct Loss 
       Time after Onset             6 months             1 Year          2 Years 
Number still followed 16 13 9 
Laboratory values    
     Bilirubin* (mg/dL) 1.5 (0.2-35.2) 0.8 (0.3-31.6) 0.8 (0.4-19.3) 
     ALT* (U/L) 112 (25-483) 91 (35-318) 48 (23-169) 
     Alk P* (U/L) 395 (94-940) 335 (153-509) 268 (87-1560) 
Chronicity score* 2.0 (0-4) 2 (1-4) 1 (1-2) 
            0   (n) 2 0 0 
            1   (n) 2 2 5 
            2   (n) 9 10 4 
            3   (n) 3 0 0 
            4   (n) 1 1 0 
    
• Of the initial 26 patients, seven died, two underwent liver transplant and eight were lost 
to follow up within two years of onset; ten before 6 months, three between 6 months and 
1 year and another four between 1 and 2 years.  
• *Mean and range of laboratory values and chronicity scores at each time point are given 
as well as the distribution of individual chronicity severe scores (0 to 4). 
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Table 4:  Demographic, Clinical and Laboratory Features by Outcome 
Feature Benign Outcome Poor Outcome p values 
 Number 7 13  
Age* (years) 64(42-83) 48 (11-80) 0.08 
Sex (Female) 4 (57%) 9 (69%) 0.65 
Race:   0.35 
     White 6 (86%) 8 (62%)  
     African American 1 (14%) 5 (38%)  
Symptoms      
     Jaundice 6 (86%) 13 (100%) 0.35 
     Itching 6 (86%) 9 (69%) 0.61 
     Fatigue 4 (57%) 6 (46%) 1.00 
     Abdominal Pain 2 (29%) 7 (54%) 0.37 
     Rash 2 (29%) 7 (54%) 0.37 
     Fever 1 (14%) 9 (69%) 0.06 
Time to onset (days) 39 (11-496) 32 (3-551) 0.53 
Initial Laboratory results    
     Bilirubin* (mg/dL) 11 (0.2-34.) 7.2 (0.4-20.2) 0.61 
     ALT* (U/L) 542 (57-1268) 276 (91-779) 0.55 
     Alk P* (U/L) 482 (281-1261) 366 (71-925) 0.23 
     R ratio* 1.5 (0.6-7.9) 1.8 (1.0-8.0) 0.22 
     ANA 2 (29%) 1 (8%) 0.27 
     SMA 1 (14%) 2 (15%) 1.00 
     Eosinophilia (>500/uL) 1 (14%) 3 (23%) 1.00 
Laboratory results at biopsy*    
Comment [HB2]: Jay:  Please revise as you think 
best in light of Editors’ suggestions. 
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     Bilirubin* (mg/dL) 7.5 (0.6-14.3) 18.5 (9.0-25.8) 0.04 
     ALT* (U/L) 121.0 (62-350) 297.5 (113-849) 0.11 
     Alk P* (U/L) 280.0 (272-828) 746.0 (321-986) 0.04 
     R ratio* 1.0 (0.6-2.6) 1.5 (0.4-3.1) 0.51 
Therapy     
     Corticosteroids 6 (86%) 10 (77%) 1.00 
      Ursodiol  4 (57%) 7 (54%) 1.00 
Liver biopsy results    
     HAI Score (0-18)* 7.0 (3-9) 4.5 (3-5) 0.23 
     Fibrosis Score (0-6)* 0 (0-2) 0 (0-1) 0.56 
     Bile Duct Injury Score (0-2)* 2.0 (0-2) 2.0 (1-2) 0.67 
     Bile Duct Loss score (0-2)* 1 (1-1) 2 (1-2) <0.001 
     Mod-severe bile duct loss* 0 (0%) 12 (92%) <0.001 
     Portal areas (PA) (n)* 14.0 (7-21) 9 (6-18) 0.30 
     Percent PA with Bile Ducts*  64% (43%-75%) 17% (0%-50%) 0.003 
Abbreviations: Alk P, alkaline phosphatase; ALT, alanine aminotransferase; ANA, antinuclear 
antibody; HAI, histology activity index; PA, portal areas; SMA, smooth muscle antibody  
* For those with biopsy done within 3 months of onset (benign =6, poor = 9) 
Poor outcome is defined as death with liver injury the primary or a contributory cause, liver 
transplantation or persistent evidence of at least moderate liver injury at the time of the last visit.  
Primary implicated agents in subjects with poor outcomes:  azithromycin in 2, herbals in 2, 
thalidomide/lenalidomide in 2; and one each for infliximab, lamotrigine, olanzapine, 
metoclopramide, montelukast, moxifloxacin, olanzapine and temozolomide. 
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Benign outcome is defined as evidence of no or only mild liver injury at the time of the last visit 
at least 6 months after onset (includes patients who died of unrelated causes).  Primary 
implicated agents:  one case each for amoxicillin/clavulanate, enalapril, herbals, lansoprazole, 
mesalamine, omeprazole and temozolomide. 
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Titles and Legends for Figures 
Figure 1: Summary Flow Diagram of how the Analytic Cohort was Developed.  Among 
1433 patients enrolled in the DILIN Prospective study between September 2004 and September 
2014, 1296 underwent full causality assessment by the time of this analysis, of whom 1056 
were considered definite, highly likely or probable drug induced liver injury.  Among these 363 
underwent liver biopsies that were available for analysis, 26 of which showed bile duct loss. 
Figure 2:  Representative Histopathology  
A, B: Loss of bile ducts due to montelukast.  A. PA infiltrated by lymphocytes and macrophages 
without discernible duct (H&E, 600x).  B. Infiltrated PA with apoptotic cell (arrow) (H&E, 400x). 
C, D: Mild bile duct paucity due to traditional Chinese medicine.  C. PA with a infiltrate of 
lymphocytes that often obscured bile ducts (arrow heads) (H&E, 400x).  D.  Chronic cholestasis 
confirmed by positive copper stain (red granules) (Copper, 600x).  E, F.  CK 7 staining showed 
extensive ductular reaction and hepatocellular CK 7 expression (E) or loss of both bile ducts 
and canals of Herring (F).  (anti-CK 7, 200x and 400x, respectively). 
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Figure 1 
  
1296 Cases Adjudicated by 
Causality Committee 
1056 Cases Adjudicated as 
Definite, Highly Likely or 
Probable 
363 Cases Underwent 
Liver Biopsy and Read by 
Central Pathologist 
337 Cases with  
No Bile Duct Loss 
26 Cases with  
Bile Duct Loss 
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Figure 2: 
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Suppl Table 1 
Clinical Centers Participating in DILIN 
University of Connecticut Health Center [2003-2008]: Drs. Herbert Bonkovsky (PI) and James Freston, Robert 
Rosson, and George Wu  
University of North Carolina Chapel Hill [2003-2016]: Drs. Paul Watkins (PI) and Paul Hayashi.  
University of Michigan Ann Arbor [2003-2016]: Drs. Robert Fontana (PI), Hari Conjeevaram and Richard 
Moseley.  
University of California, San Francisco, California Pacific Medical Center [2003-2013]: Drs. Timothy Davern 
(PI), and Mauricio Bonacini  
Indiana University-Purdue [2003-2016]: Drs. Naga Chalasani (PI), Raj Vuppalanchi, Marwan Ghabril  
Icahn School of Medicine at Mount Sinai [2013-2016]: Drs. Joseph A. Odin (PI), Jawad Ahmad (co-PI),  
Mayo Clinic College of Medicine [2009-2013]: Dr. Jay Talwalkar (PI).   
University of Pennsylvania [2009-2013]: Dr. Raj Reddy (PI).  
University of Southern California and University of California-Los Angeles [2009-2016]: Drs. Andrew Stolz (PI), 
Neil Kaplowitz, Francisco Durazo 
Albert Einstein Medical Center and University of Pennsylvania [2008-2016]: Dr. Vic Navarro (PI), Raj Reddy.   
University of Texas-Southwestern [2008-2013]: Drs. William Lee and Lafaine Grant. 
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Suppl Table 2 
Scoring System for Severity of Chronicity 
Score Description ALT Alk P Total 
Bilirubin 
INR 
      
0 None Normal Normal Normal 
[≤1.2 
mg/dL] 
< 1.5 
[or missing] 
      
1 Mild ALT 1-3 x ULN  or Alk P 1-2 x ULN or total 
Bilirubin 1.3-2.4 mg/dL 
[Any one or several of the above]* 
< 1.5 
[or missing] 
      
2 Moderate ALT > 3 x ULN or Alk P > 2 x ULN < 2.5 mg/dL < 1.5 
[or missing] 
      
3 Moderate-
severe 
ALT > 1 x ULN or Alk P > 1 x ULN ≥ 2.5 mg/dL < 1.5 
      
4 Severe ALT > 1 x ULN or Alk P > 1 x ULN ≥ 2.5 mg/dL ≥ 1.5 ** 
Chronicity is scored at 6, 12 and 24 months using the results closest to the dates that are 182, 365 and 730 
days after laboratory defined onset of DILI.  The allowable range of dates (windows) is 182-300 days for 6 
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months, 300-600 days for 12 months and 600-900 days for 24 months.   Dates for the 6 month specimen are 
preferred to be after 182 days, but if none are available before day 300, an earlier date after 160 days can be 
used. Missing values for INR can be replaced by values obtained within 60 days of the sample.  Results that 
do not fit any of the patterns below or that have missing essential results are flagged and determined 
“manually” by a DILIN investigator after re-review of the case with all the laboratory results.  Scores that still 
cannot be resolved and all cases without laboratory results beyond 160 days of onset are considered 
“unknown”. 
* Cases that are assigned a score of “mild” based upon bilirubin levels alone or normal ALT and Alk P but 
bilirubin ≥ 2.5 mg/dL require manual review by a DILIN investigator to verify that the bilirubin elevation is due to 
liver injury (and not hemolysis, Gilbert’s syndrome, sepsis, and so forth). 
** or other symptoms, signs or evidence of hepatic failure (ascites, encephalopathy) 
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Suppl Table 3: Demographic, Clinical and Laboratory Features of Subjects who Underwent Liver 
Biopsies with Initial R Values ≤ 8 with VBDS [n =26] vs those without VBDS [n= 193] 
Feature Bile Duct Loss 
(n=26) 
No Duct Loss 
(n=193) 
     P values 
Sex (Female) 14 (54%) 109 (57%) 0.84 
Race   0.10 
           White 
           Black 
           Other 
20 (77%) 
6 (23%) 
0 
160(83%) 
20(10%) 
13 (7%) 
 
 
Age* (years) 54 (11-87) 53 (14-86) 0.49 
Symptoms (any) 25 (96%) 184 (95%) 1.00 
      Jaundice 25 (96%) 158 (82%) 0.09 
      Itching 20 (77%) 125 (65%) 0.27 
      Fatigue 11 (42%) 99 (51%) 0.41 
      Abdominal Pain 11 (42%) 83 (43%) 1.0 
      Rash 10 (39%) 56 (29%) 0.36 
      Fever 12 (46%) 60 (31%) 0.18 
Eosinophils >500/µL 4 (15%) 31/190 (16%) 1.00 
ANA 5 (19%) 49/191 (26%) 0.63 
SMA 4/25 (16%) 35/183 (19%) 1.00 
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Latency* (days) 38 (3-551) 40 (1-7046) 0.32 
Initial:  Bilirubin* (mg/dL) 7.2 (0.2-34.1) 5.6 (0.2-32.5) 0.40 
               ALT* (U/L) 296 (57-1,268) 276(6-3658) 0.61 
               Alk P* (U/L) 368 (71-1,1261) 273 (52-1952) 0.02 
               R ratio* 1.7 (0.6-8.0) 2.8 (0.1-7.9)      0.38 
Peak: Bilirubin* (mg/dL) 21.5 (0.6-59) 13.9 (0.4-55.0)       0.003 
            ALT* (U/L) 497 (97-3,388) 381 (9.0-5831)         0.11 
            Alk P* (U/L) 804 (357-2,414) 379 (95-2865)     <0.001 
            INR* 1.6 (1.0-6.8) 1.2 (0.9-12.9)      0.032 
Bilirubin peak to <2.5 mg/dL 
(median in days) 
70 (n=23) 36 (n=165)          0.005 
Corticosteroid therapy  20 (77%) 74/189 (39%)      <0.001 
Ursodiol therapy 16 (62%) 63/189 (33%)      0.008 
Severity Score * 3.5 (1-5) 3.0 (2-4)      0.02 
Severity Score:   
       1 (mild) 
      2 or 3 (moderate) 
       4 or 5 (severe or fatal)        
 
1 (4%) 
12 (46%) 
13 (50%) 
 
25 (13%) 
112 (58%) 
56 (29%) 
     0.02 
      
 
Chronicity at 6 months 15/16 (94%) 59/125 (47%)     <0.001 
Liver Transplantation ‡ 2 (8%) 9 (5%)       0.62 
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Death, all causes ‡ 7 (27%) 18 (9%)       0.02 
           Primary   2 (8%) 8 (4%)   
           Contributory 3 (12%) 5 (3%)   
           Unrelated 2 (8%) 5 (3%)   
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Suppl Table 4 
Results of early biopsies that did not show bile duct loss in patients in whom later biopsies did show 
duct loss compared to those of patients that showed bile duct loss on early biopsies 
Feature Early Biopsy Shows 
No Duct Loss 
n=6 
Early Biopsy 
Shows Duct Loss 
n=19 
p value 
Time after onset to liver 
biopsy (days) 
 
14 (5-88) 11 (2-377) 0.68 
Histology Activity Index* 
   (0-18) 
4.0 (2-12) 5 (3-9) 0.52 
Fibrosis score* 
   (0-6) 
2 (1-4) 1 (0-4) 0.03 
Copper score 
   (0-2) 
0 (0-1) 0 (0-2) 0.38 
Copper positivity (1 or 2) 
number (%) 
1 (17%) 6/17 (35%) 0.62 
Bile Duct Injury score 
   (0-2) 
0.5 (0-2) 2 (0-2) 0.10 
Bile duct injury (1 or 2)  
number (%) 
3 (50%) 16/17 (94%) 0.04 
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Number of Portal Areas 
seen 
7 (4-13) 14 (7-28) 0.002 
Number of Portal Areas 
with ducts 
3 (3-9) 3 (0-15) 0.97 
Fraction of Portal Areas 
with bile ducts (%)  
65% (15%-75%) 40% (0%-75%) 0.14 
 
Data given are median values (ranges). 
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Suppl Material:  Detailed Overview of DILIN 
The Network has consisted of multiple clinical centers, a central data coordinating center and a sample and 
data repository maintained by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).  
The principal investigators and locations of the clinical centers have varied over the course of the study and 
are provided in Supplementary Table 1.  The Duke Clinical Research Institute (DCRI: Durham, NC) has 
served as the data coordinating center since the inception of DILIN.  The DILIN Prospective Protocol allowed 
the clinical centers to enroll all patients with liver injury suspected to be due to drugs or herbal and dietary 
supplements (HDS) seen at their institutions within six months of onset who agreed to participate.  Extensive 
demographic, clinical, laboratory, imaging and histologic material was retrieved from the patients’ medical 
records, and a medical histories and physical examinations were performed at the time of enrollment.   In 
addition, serum, plasma and whole blood were taken to perform laboratory tests that might not have been done 
initially and to provide samples stored at the NIDDK repository. Patients were asked to return in six months 
and, if liver tests, physical examination or imaging studies remained abnormal, again at 12 and 24 months after 
enrollment.  All data were entered into an electronic database maintained at the DCRI.  A more nearly 
complete description of the Prospective Protocol has been published13 and the full text is available on the 
DILIN public website at: www.DILIN.org. 
All details of the Prospective Protocol and consent forms were approved by local Institutional Review Boards 
as well as by a central Data Safety Monitoring Board established for this study by the NIDDK.  All patients 
provided written informed consent. 
  
Page 49 of 76
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
Suppl Material:  List of Representative Case Summaries. 
Case 1: 48 year old Hispanic woman treated with cephalexin, lamotrigine and moxifloxacin developed DRESS 
syndrome followed by severe progressive cholestatic liver injury resulting in death 71 days after onset 104-
0054 [8], Cefalexin. 
Case 2: 47 year old African American woman exposed to moxifloxacin developed cholestatic hepatitis followed 
by progressive cholestasis leading to liver transplantation 13 months after onset.  104-0121 [10], Moxifloxacin 
Case 3: 19 year old Caucasian woman exposed to olanzapine and azithromycin developed fever, rash and 
cholestatic hepatitis with prolonged course and persistent liver test abnormalities for 2 years.  109-0004 [21], 
Olanzapine 
Case 4: 20 year old African American woman developed toxic epidermal necrolysis and cholestatic hepatitis 
after exposure to azithromycin and still had symptoms, disability and abnormal liver tests 2 years later.  104-
0123 [11], Azithromycin 
Case 5: 56 year old African American man developed cholestatic hepatitis after use of Gluco-Ease plus and 
still had pruritus and abnormal liver tests two years later. 109-0017 [24], Gluco-Ease Plus 
Case 6: 81 year old Caucasian man developed cholestatic hepatitis shortly after 10 day course of 
amoxicillin/clavulanate which resolved completely within 6 months.  102-0094 [3], Amoxicillin/Clavulanate  
Case 7: 66 year old Caucasian woman developed jaundice while taking multiple herbal medications and 
mixtures of supplements with jaundice resolving within 3 months but prolonged liver tests abnormalities that did 
not resolve completely until two years after onset. 108-0061 [20], HDS 
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Clinical Summaries 
Clinical Summary: Case #1  
Cefalexin/Lamotrigine/Moxifloxacin 
Vanishing Bile Duct Syndrome/DRESS 
 
A 48 year old Hispanic woman had a long history of bipolar illness, depression and multiple suicide attempts.  After an 
admission for another suicide attempt by overdosage with lorazepam, levothyroxine, dextropropoxyphene, 
acetaminophen, and venlafaxine, she was switched to a regimen of escitalopram, aripiprazole and lamotrigine (25 mg 
twice daily). During that admission for overdose, her liver tests were completely normal. After discharge she was treated 
with cefalexin for a superficial foot infection and was later given moxifloxacin. Approximately one month after starting 
lamotrigine, two weeks after starting cefalexin (and 6 days after stopping it), and 8 days after starting moxifloxacin (which 
she took for 4 days), she developed a diffuse erythematous rash and fever. The rash spread and was pruritic and slightly 
painful, and she was hospitalized for management and observation. On admission, she had fever and rash, but was not 
jaundiced. The serum bilirubin was 0.4 mg/dL, ALT 316 U/L [4.9 times ULN], AST 359 U/L [9 times ULN], alkaline 
phosphatase 108 U/L [normal], albumin 3.0 g/dL and INR 1.1. Over the next few days the liver enzymes worsened and 
she became jaundiced. While the cefalexin and moxifloxacin had been stopped, lamotrigine and her other psychotropic 
agents were continued. She had no previous history of liver disease or risk factors for viral hepatitis. She did not drink 
alcohol but had a history of drug rash in response to penicillin. Tests for hepatitis A, B, C and E were negative as were 
ANA and SMA. Ultrasound showed no evidence of biliary obstruction although she did have gallstones and a contracted 
gallbladder. She was treated with corticosteroids and eventually discharged, but returned to the hospital several days later 
with worsening rash and fever. At this point, lamotrigine and aripiprazole were stopped. The serum bilirubin had risen to 
15.5 mg/dL, ALT 603 U/L, alkaline phosphatase 1008 U/L [R ratio = 1.8], and INR 1.1. A liver biopsy (done a month after 
initial presentation and when bilirubin reached 26.3 mg/dL) showed severe cholestatic hepatitis and paucity of bile ducts 
compatible with vanishing bile duct syndrome (among 6 portal areas none had identifiable bile ducts: duct fraction = 0%). 
She was treated with prednisone and ursodiol but became increasingly jaundiced and INR rose to 2.6. She was not 
considered a liver transplant candidate and was discharged to hospice care where she died two and a half months after 
initial presentation. This case was reviewed and judged to be highly likely drug induced liver injury but there was 
disagreement regarding the responsible agent: cefalexin was considered the probable cause, lamotrigine possible and 
moxifloxacin unlikely (RUCAM scores 6 to 7). The skin manifestations and fever were considered compatible with DRESS 
syndrome. The severity was scored as 5+ (fatal). The cause of death was considered hepatic failure due to vanishing bile 
duct syndrome. 
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Serial Laboratory Results (selected) 
Date 
Days from 
Onset 
ALT 
(U/L) 
Alk P 
(U/L) 
Bilirubin 
(mg/dL) 
Event 
5/2/2006 -34 28 102 0.1 Normal values 
5/8/2006 -28 
   
Lamotrigine started 
5/22/2006 -13    Cefalexin started [7 days] 
6/4/2006 -1 
   
Onset of rash and fever 
6/5/2006 0 316 108 0.4 Hospital admission, R = 6.1 
6/6/2006 1 737 153 0.4 
 
6/7/2006 2 1505 313 1.4 
 
6/8/2006 3 1808 400 3.1 INR 1.2 
6/13/2006 8 794 839 9.0 
 
6/15/2006 10 603 1008 15.5 Lamotrigine stopped, R = 1.8 
6/20/2006 15 621 1123 17.9 
 
6/23/2006 18 488 1428 20.8 INR 1.5 
7/5/2006 30 264 1493 28.0 R = 0.6 
7/12/2006 37 337 2101 29.0 Liver biopsy: bile duct loss 
7/17/2006 42 173 1429 36.1 
 
7/19/2006 44 128 1817 44.5 INR 2.2 
7/24/2006 49 165 1948 48.6 Discharged to hospice care 
8/6/2006 62 268 1737 56.6 
 
8/15/2006 71 
   
Death 
Normal values < 65 < 135 < 1.2   
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Summary Table 
Feature Result 
Implicated Agent(s) Lamotrigine, cefalexin, moxifloxacin 
Time to onset 28 days, 14 days, 8 days 
Enzyme pattern Initially hepatocellular (R=6.1), later cholestatic (R<1.0) 
HEV testing Anti-HEV IgG and IgM neg 
HCV testing Anti-HCV and HCV RNA neg 
Hospitalization Yes 
Prednisone Yes  
Ursodiol Yes 
Chronicity Unknown, died within 3 months 
Severity 5+ (Fatal) 
Causality Overall 2 (Highly likely), lamotrigine 4 (possible), 
cefalexin 3 (probable), moxifloxacin 5 (unlikely) 
RUCAM 7 (Probable) 
Concomitant medications 17 (meloxicam, aripiprazole, escitalopram) 
Comment Died of liver failure 71 days after onset  
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Clinical Summary: Case #2: Moxifloxacin 
Vanishing Bile Duct Syndrome  A 47 year old African American woman with mild diabetes was hospitalized for 2 days with suspected pneumonia and treated with intravenous followed by oral moxifloxacin. She began to feel ill within days of starting the antibiotic and stopped it early. She then developed dark urine, pruritus and jaundice and sought medical attention again. She had no previous history of liver disease, alcohol abuse, risk factors for viral hepatitis or drug allergies.  Her other medical conditions (and medications) included type 2 diabetes (metformin, fish oil) and allergic rhinitis (cetirizine, acetaminophen). On presentation 8 days after starting and 4 days after stopping moxifloxacin, she was jaundiced and had a mild rash. Laboratory tests showed a total bilirubin of 7.2 mg/dL, ALT 266 U/L (6.7 times ULN), AST 131 U/L (3.7 times ULN) and alkaline phosphatase 392 U/L (3.9 times ULN) yielding an R ratio of 1.7 (cholestatic). Serum albumin was 4.4 g/dL and INR 1.0. There was a slight eosinophilia (6%). Tests for hepatitis A, B, C and E were negative (she had IgG anti-HEV, but no IgM reactivity). Both ANA and SMA were negative and imaging of the liver by ultrasound and CT scan showed no evidence of biliary obstruction. She was monitored on no therapy but jaundice deepened and worsened. She subsequently remained jaundiced and was disabled from fatigue and weakness. Eleven months after onset of the liver disease, jaundice began to worsen with serum bilirubin rising to 33.3 mg/dL and she underwent successful liver transplantation 13 months after initial presentation. The explant showed chronic cholestatic liver injury with marked cholestasis and mild portal and lobular inflammation.  There was profound ductopenia: in 20 consecutive portal areas, none had bile ducts (bile duct fraction = 0%). Even the largest portal areas lacked ducts.  There was marked ductular reaction. This case was scored as severe (4+, jaundice, hospitalization and prolongation of INR). The causality score was 2 (highly likely) and RUCAM score was 6 (probable).  The abrupt onset, immunoallergic features, severe cholestatic hepatitis and persistent cholestatic injury are typical of drug-induced vanishing bile duct syndrome, most likely due to moxifloxacin hepatotoxicity. The patient was "case 3" in the publication: Orman ES, Conjeevaram HS, Vuppalanchi R, Feston JW, Rochon J, Kleiner DE, Hayashi PH for the DILIN Research Group. Clinical and histological features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol 2011; 9: 517-523. 
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 Photomicrograph showing portal area in explant liver lacking a bile duct. (H&E, 200x) 
 Copper stain with strong positive reaction in hepatocytes near portal area (Copper, 400x) Serial Laboratory Results (Selective)  
Date Days from Onset ALT (U/L) Alk P (U/L) Bilirubin (mg/dL) Event 6/25/2008 -8 62 99 0.7 Moxifloxacin started 6/29/2008 -4    Moxifloxacin stopped 
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Date Days from Onset ALT (U/L) Alk P (U/L) Bilirubin (mg/dL) Event 7/3/2008 0 266 392 7.2 Symptom Onset, R = 1.7 7/5/2008 2 173 278 6.0  7/9/2008 6 206 356 8.4  7/14/2008 11 252 366 9.8 Liver Biopsy: Bile duct loss 7/28/2008 25 250 326 13.5  8/4/2008 32 257 330 15.1  8/19/2008 47 158 310 13.9  9/3/2008 62 118 209 11.9  9/18/2008 77 120 395 12.4  0/14/2008 103 343 450 11.5  11/5/2008 125 293 513 13.8  3/13/2009 253 60 357 13.8 6 mo chronicity score = 4 4/22/2009 293 93 224 13.6 INR 2.2 5/28/2009 329 38 281 22.8  6/15/2009 347 62 198 26.0  7/14/2009 376 23 113 33.3 1 year chronicity score = 4 7/15/2009 377    Liver transplant 
Normal Values <40 < 125 < 1.2      
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Summary Table Feature Result Implicated Agent(s) Moxifloxacin Time to onset 8 days Enzyme pattern Cholestatic (1.7) HEV testing Anti-HEV IgG pos, IgM neg HCV testing Anti-HCV and HCV RNA neg Hospitalization Yes Prednisone Yes Ursodiol Not mentioned Chronicity Yes, chronicity score = 4+ at 6 mo and 1  year Severity 4+ (Severe, jaundiced, liver failure) Causality 2 (Highly likely)  RUCAM 6 (Probable)  Concomitant medications 4 (Metformin, cetirizine) Comment Liver transplantation 1 year after onset 
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Clinical Summary: Case #3  
Olanzapine/Azithromycin:  
DRESS Syndrome: Bile Duct Loss 
 
A 19 year old Caucasian woman developed maculopapular rash followed by fever within 3 weeks of starting 
olanzapine (25 to 30 mg daily) for acute psychosis. She also complained of shortness of breath and 
eosinophilia and was thought to have pneumonia. She was treated with azithromycin (250 mg daily) but 
returned two days later with worsening symptoms, fatigue, nausea, itching and a maculopapular rash at which 
point olanzapine and azithromycin were stopped. She had no previous history of liver disease, alcohol abuse, 
risk factors for viral hepatitis or drug allergies. She had a fairly recent onset of psychosis and mania and had 
received multiple drugs in the previous two months including aripiprazole, clonazepam, haloperidol, lithium, 
lorazepam, oxcarbazepine, quetiapine and risperidone.  Other medications included ibuprofen, 
acetaminophen, benzatropine, ceftriaxone, dexamethasone, enoxaparin, and senna.  Laboratory testing 
initially showed a serum bilirubin of 1.2 mg/dL, ALT 255 U/L [3.6 times ULN], AST 194 U/L [4.9 times ULN] and 
alkaline phosphatase 306 [2.3 times ULN].  The R ratio was 1.6 (cholestatic).  She was admitted for evaluation 
and despite discontinuation of olanzapine and azithromycin, serum bilirubin levels continued to rise and 
peaked at 54.8 mg/dL three weeks later. Serum INR rose to 1.7 but then fell into the normal range. Tests for 
hepatitis A, B, C and E were negative as was ANA while SMA was weakly positive (titer not available). Imaging 
of the liver showed hepatomegaly without evidence of gallstones or biliary obstruction. A liver biopsy done 20 
days after onset showed mild cholestatic hepatitis.  Only 3 portal areas were present in the biopsy sample 
available for review and all 3 had identifiable bile ducts.  There was no fibrosis and no ductular reaction. A 
second biopsy was performed 107 days after onset showed severe cholestasis, but the recuts available for 
review lacked any portal areas. She received no specific therapy and remained jaundiced for 6 months, but 
serum bilirubin ultimately fell into the normal range. In follow up, she continued to have mild symptoms of 
fatigue and itching and serum enzyme levels remained moderately elevated.  A repeat liver biopsy done almost 
2 years after onset showed chronic cholestatic liver injury with moderate inflammation and bile duct injury with 
bile duct loss; among 6 portal areas in the biopsy sample, only 2 had identifiable bile ducts (bile duct fraction = 
33%). Marked ductular reaction was present spanning between portal areas and accompanied by bridging 
fibrosis. The case was reviewed and considered to be very likely drug induced liver injury, probably due to 
olanzapine. The RUCAM score was 6 (probable). Azithromycin was considered only possibly responsible. The 
use of azithromycin and recent receipt of other psychotropic, potentially hepatotoxic agents, made more 
definitive assessment of causality difficult. The severity score was 4+ (severe). The initial clinical presentation 
was typical of DRESS syndrome.  Inadequate sampling may account for the failure to observe bile duct loss on 
the first two biopsies.  
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Marked ductular reaction and focally severe inflammation in the portal tracts in the third biopsy (200x) 
 
Masson stain showing bridging fibrosis associated with ductular reaction.  
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Serial Laboratory Results 
Date Days from Onset ALT (U/L) Alk P (U/L) Bilirubin (mg/dL) Event 1/21/2009 -21    Olanzapine started 1/22/2009 -20 37 71 0.2 Normal 2/7/2009 -4    Onset of symptoms 2/9/2009 -2    Azithromycin started 2/11/2009 0 255 306 1.2 Both drugs stopped 2/13/2009 2 237 317 2.0 CT scan 2/15/2009 4 275 517 5.0  2/18/2009 7 268 655 7.8  2/24/2009 13 184 384 18.1  2/28/2009 17 220 433 25.8  3/3/2009 20 339 547 35.5 Liver biopsy: cholestasis 3/10/2009 27 152 171 32.6  3/31/2009 48 143 236 23.0  4/13/2009 61 201 327 13.5  4/27/2009 75 288 505 2.2  5/29/2009 107 180 821 21.0  6/19/2009 128 181 794 14.1 6 month chronicity score = 3 7/15/2009 154 110 639 9.3  9/10/2009 211 282 569 2.7  1/30/2009 292 172 441 1.3  2/11/2010 365 214 441 0.9 1 year chronicity score = 2 8/17/2010 552 223 424 0.4  1/24/2010 651 154 264 0.4 Liver biopsy: bile duct loss 3/24/2011 771 169 268 0.4 2 year chronicity score = 2 
Normal Values < 35 < 135 < 1.2 
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Summary Table 
Feature Result 
Implicated Agent(s) Olanzapine, Azithromycin 
Time to onset 21 days, 2 days 
Enzyme pattern Cholestatic (R ratio = 1.6) 
HEV testing Anti-HEV IgG neg 
HCV testing Anti-HCV neg, HCV RNA neg 
Hospitalization Yes 
Prednisone No  
Ursodiol Not mentioned 
Chronicity Yes, chronicity score 3+ at 6 mo, 2+ at 1 and 2 yrs 
Severity 4+ (Jaundiced, hospitalized, INR above 1.5) 
Causality Overall 2 (Highly likely), Olanzapine 3 (Probable), 
Azithromycin 4 (Possible).  
RUCAM 6 (Probable) 
Concomitant Medications 17 (Oxcarbazepine, Risperidone, Ceftriaxone) 
Comment DRESS, VBDS, prolonged cholestasis 
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Clinical Summary: Case #4 Azithromycin/Ibuprofen:  
VBDS, Toxic Epidermal Necrolysis 
A 20 year old previously healthy, African-American college student developed sore throat, fever and cough and 
was given ibuprofen and later azithromycin without improvement whereupon she rapidly developed worsening 
throat pain, painful swallowing, progressively generalized rash, fever and jaundice. She was dehydrated and 
had blistering lesions over her body including mouth and vagina. She was hospitalized and both ibuprofen (6 
days) and azithromycin (2 days) were stopped. She had no history of liver disease, alcohol abuse, risk factors 
for viral hepatitis or drug allergies.  She was taking no other medications or herbal preparations.  Physical 
examination was marked by jaundice, skin rash, fever, liver enlargement and splenomegaly. Initial laboratory 
results showed serum bilirubin 3.7 mg/dL, 140 U/L [4 times ULN], AST 269 U/L [9 times ULN], alkaline 
phosphatase 71 U/L [0.5 times ULN] and albumin 4 g/dL. Skin biopsies were consistent with toxic epidermal 
necrolysis. She became progressively more jaundiced and was transferred to an intensive care unit where she 
developed respiratory failure and required intubation. Tests for hepatitis A, B, C and E were negative as were 
tests for Ebstein Barr Virus, cytomegalovirus and herpes simplex infections. She received intravenous 
immunoglobulin and multiple antibiotics. She was positive for ANA but negative for SMA, double stranded DNA 
and anti-cardiolipin. Her ICU stay was complicated by pneumothorax, respiratory and cardiac arrest and she 
was treated with multiple courses of antibiotics and high doses of corticosteroids. She became intensely 
jaundiced and had persistent elevations in serum aminotransferase levels and alkaline phosphatase. 
Eventually, she recovered enough to leave the ICU and then the hospital but was slow to improve and still had 
liver test abnormalities when seen 6, 12 and 24 months after onset. An initial liver biopsy on day 37 (when 
serum bilirubin was 17.3 mg/dL) showed a mild acute hepatitis without cholestasis. The bile ducts were 
considered adequate and did not show injury.  On re-review, bile ducts were present in 4 of 6 portal areas on 
the sample (bile duct fraction = 67%).   A repeat liver biopsy done 11 months after onset (serum bilirubin ~ 3.0 
mg/dL) showed chronic cholestatic liver injury with mild inflammation, zone 3 cholestasis and marked bile duct 
loss: among 13 portal areas only 2 had identifiable bile ducts (bile duct fraction = 15%). Ductular reaction was 
present, but not striking. In follow up, she suffered severe disability with neuropathy, fatigue, weakness, and 
difficulty maintaining her weight (falling to 75 lbs at one year). The clinical course and outcome were 
compatible with severe toxic epidermal necrolysis and cholestatic hepatitis with vanishing bile duct syndrome.  
The case was judged as highly likely drug-induced liver injury, highly likely due to azithromycin and only 
possibly due to ibuprofen.     
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Portal area from second biopsy with mild inflammation, lacking a bile duct (400x) 
 
Copper was focally present (arrow) (Copper stain, 600x)  
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Serial Laboratory Results (Selected) 
Date Days 
ALT 
(U/L) 
Alk P 
(U/L) 
Bilirubin 
(mg/dL) 
Event 
10/9/2008 -2 
   
Azithromycin started 
10/11/2008 0 140 71 3.7 Admission, R ratio 7.3 
10/15/2008 4 247 141 4.8 INR 1.0 
10/17/2008 6 177 190 9.3 
 
10/25/2008 14 89 424 11.7 R ratio = 0.8 
11/1/2008 21 204 679 14.9 
 
11/10/2008 30 258 518 18.3 
 
11/14/2008 34 237 522 20.0 
 
11/16/2008 36 234 459 17.3 Liver biopsy: cholestasis, hepatitis 
11/27/2008 47 175 323 13.4 
 
12/22/2008 72 431 460 12.7 
 
1/30/2009 111 529 328 13.1 
 
2/16/2009 128 221 294 11.1 
 
4/14/2009 185 351 363 8.1 6 month chronicity score = 3 
6/16/2009 248 359 449 3.5 
 
8/27/2009     Liver biopsy: bile duct loss, copper 
9/30/2009 354 318 261 1.3 1 year chronicity score = 2  
11/23/2009 408 311 406 1.3 
 
10/25/2010 744 133 298 0.8 2 year chronicity score = 2 
Normal values < 35 < 130 < 1.2 
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Summary Table 
Feature Result 
Implicated Agent(s) Azithromycin 
Time to onset 2 days 
Enzyme pattern Hepatocellular (7.3), then cholestatic (<1.0) 
HEV testing Anti-HEV IgG and IgM neg 
HCV testing Anti-HCV and HCV RNA neg 
Hospitalization Yes 
Prednisone Yes 
Ursodiol Not Mentioned 
Chronicity Yes, chronicity score 3+ 6 mo, 2+ at 1 and 2 years 
Severity 4+ (jaundice, hospitalization, INR >1.5) 
Causality 2 (highly likely) 
RUCAM 1 (unlikely) 
Concomitant Medications 2 (Ibuprofen) 
Comment TEN 
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Clinical Summary: Case #5 
 HDS: Gluco-Ease Plus: Bile Duct Loss 
 
A 56 year old African American man with diabetes on long term insulin therapy began an herbal product for 
glucose control called "Gluco-Ease Plus" and 3-4 months later he began to have itching, followed by jaundice 
and fatigue (the timing of onset of symptoms was somewhat unclear). He had no history of liver disease, 
alcohol abuse, drug allergies or risk factors for viral hepatitis. His only other medications were insulin, lisinopril, 
and low dose aspirin which he had been taking for several years. He had taken fish oil and opuntia 
Streptacantha briefly a few months before the onset of jaundice. On presentation he was jaundiced but had no 
fever or rash.  When laboratory tests were taken, serum bilirubin was 1.6 mg/dL, ALT 276 U/L [6.1 times ULN], 
AST 200 U/L [5 times ULN], and alkaline phosphatase 679 U/L [5.7 times ULN]. The R ratio was 1.1 
(cholestatic). Serum albumin was 2.9 g/dL and INR done two weeks later was normal (0.96). Tests for hepatitis 
A, B, C and E were negative and both ANA and SMA were unreactive. Imaging of the liver by ultrasound, CT 
and MRI suggested minor dilatation of intrahepatic bile ducts and he underwent ERCP which was normal. A 
liver biopsy showed a chronic hepatitis-like injury without obvious bile duct injury or loss. There was no bile 
accumulation. He had stopped the Gluco-Ease Plus shortly before hospitalization. His serum bilirubin rose to a 
peak of 9.5 mg/dL two weeks later and then began to fall. He was jaundiced for almost three months and 
serum enzymes decreased but remained elevated.  One year after onset, the serum ALT was 63 U/L and 
alkaline phosphatase 479 U/L and he underwent a second liver biopsy, which showed chronic cholestasis with 
pseudoxanthomatous change and copper accumulation.  There was only mild bile duct loss: among 12 portal 
areas, 9 had identifiable bile ducts (bile duct fraction =75%).  There was no ductular reaction but there was 
definite periportal fibrosis.  When seen more than two years after onset, his serum ALT was 109 U/L and 
alkaline phosphatase 739 U/L, but bilirubin was normal (0.8 mg/dL). He continued to complain of occasional 
pruritus and fatigue. This case was reviewed and judged to be probably drug induced liver injury from the 
Gluco-Ease Plus. The listed ingredients of this product include: Uva Ursi leaves, Couch Grass, Jambul seed, 
Shave Grass (Horsetail), Huckleberry leaves, Prince's Pine, Gymnema Sylvestre. The course and outcome are 
compatible with severe cholestatic hepatitis with partial vanishing bile duct syndrome. The ultimate prognosis is 
uncertain.  
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Masson trichrome stained section of second biopsy showing periportal fibrosis (200x).  
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Serial Laboratory Results 
Date Days from Onset ALT (U/L) Alk P (U/L) Bilirubin (mg/dL) Event 
3/15/2009 -136 
   
Gluco-Ease Plus started 
7/15/2009 -14 
   
Symptom onset: Agent stopped 
7/29/2009 0 276 679 1.6 
 
7/30/2009 1 267 715 1.7 
 
8/2/2009 4 374 706 1.7 Liver biopsy #1  
8/14/2009 16 255 910 4.3 CT Scan  
8/16/2009 18 200 938 9.5  
8/20/2009 22 233 816 5.7 ERCP: normal 
8/28/2009 30 211 896 6.5 
 
9/9/2009 42 108 761 3.9 
 
10/20/2009 83 89 712 1.8 
 
11/23/2009 117 91 686 1.5 
 
12/21/2009 145 90 455 1.1 
 
3/25/2010 239 48 405 1.0 6 month chronicity score = 2 
4/12/2010 257 50 371 0.9 
 
5/7/2010 282 49 332 1.0 
 
6/1/2010 307 62 439 0.9 
 
7/6/2010 342 63 479 1.2 1 year chronicity score = 2 
10/26/2010 454 153 692 0.9 
 
1/14/2011 534 60 452 0.8 Liver biopsy #2: bile duct loss 
4/11/2011 621 54 515 1.0 
 
5/31/2011 671 47 505 0.8 2 year chronicity score = 2 
10/31/2011 824 109 739 
 
3 year chronicity score = 2 
Normal Values < 45 < 120 < 1,2 
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Summary Table 
Feature Result 
Implicated Agent(s) HDS: Gluco-Ease Plus 
Time to onset 136 days 
Enzyme pattern Cholestatic (R ratio = 1.1) 
HEV testing Anti-HEV IgG neg 
HCV testing Anti-HCV neg  
Hospitalization Yes 
Prednisone No  
Ursodiol Not mentioned 
Chronicity Yes, chronicity score 2+ at 6 mo,1 and 2 years 
Severity 3+ (Jaundiced, hospitalized) 
Causality 3 (Probable) 
RUCAM 6 (Probable) 
Concomitant Medications 3 (Lisinopril, Aspirin, Insulin) 
Comment VBDS with chronic symptoms 
  
Page 69 of 76
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
Clinical Summary: Case #6  
Amoxicillin/Clavulanate 
Bile duct loss with prompt recovery 
 
An 81 year old Caucasian man with mild dementia, benign prostatic hypertrophy and chronic obstructive 
pulmonary disease underwent minor outpatient surgery for excision of cysts on his face and back and was 
prescribed a 10 day course of amoxicillin/clavulanate (875/125 mg twice daily). Two weeks later he underwent 
repeat cyst excision and was given doxycycline (100 mg twice daily) for 7 days. During this second course of 
antibiotics he developed nausea, fatigue, abdominal discomfort, dark urine and pruritus followed by jaundice. 
He denied fever or rash. He had no history of liver disease, drug allergies, alcohol abuse or risk factors for viral 
hepatitis. His other medications included finasteride and tamsulosin for prostatism, alprazolam for sleep and 
trazodone for depression. He also was taking a multivitamin and potassium chloride. These he had taken for 
more than a year. He denied other over-the-counter or herbal medications. On initial examination, he was 
jaundiced but did not have fever, rash or other signs of chronic liver disease. Laboratory testing showed a total 
bilirubin of 16.6 mg/dL, ALT 221 U/L [3.4 times ULN], AST 144 U/L [3.6 times ULN] and alkaline phosphatase 
482 U/L [3.6 times ULN.  The R ratio was 1.0. Serum albumin was 3.3 g/dL and INR (taken 3 days later) 1.47. 
Tests for hepatitis A, B and C were negative; tests for anti-HEV were not available. Serum ANA and SMA were 
negative. Ultrasound and CT scan of the abdomen were normal, except for sludge in the gall bladder. A liver 
biopsy done 4 days after admission showed cholestatic hepatitis with mild inflammation, marked canalicular 
cholestasis, focal bile ductular reaction, bile duct injury and mild bile duct loss: among 14 portal areas, only 10 
had identifiable bile ducts (bile duct fraction = 71%). Trazodone and doxycycline were stopped on admission. 
He began to improve and was discharged after one week with serum bilirubin of 12.2 mg/dL. In follow up 1, 2 
and 6 months later he was asymptomatic and all liver tests were normal. This case was scored as 3+ in 
severity (jaundice and need for hospitalization). A review group judged the case as definite drug-induced liver 
injury from amoxicillin/clavulanate. The RUCAM score was 8 (highly probable). Typical of the course was the 
intense cholestasis with itching arising in an elderly man 1-2 weeks after a course of the antibiotic. The timing 
of onset was considered unlikely to be due to doxycycline induced liver injury which is quite rare and usually 
hepatocellular. The finding of bile duct loss on liver biopsy was concerning but did not seem to presage a 
subsequent prolonged cholestasis or development of vanishing bile duct syndrome.  
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Serial Laboratory Results 
Date Days from Onset ALT (U/L) Alk P (U/L) Bilirubin (mg/dL) Event 
2/7/2008 -21 
   
Surgery, Amox/Clav started 
2/16/2008 -12 
   
Amox/Clav stopped 
2/21/2008 -7    Doxycycline started 
2/26/2008 -2 
   
Symptom onset 
2/28/2008 0 221 482 16.6 Admission, R ratio = 1.0 
2/29/2008 1 183 411 21.9 Ultrasound, CT scan 
3/1/2008 2 153 355 18.5 INR 1.47, albumin 2.8 
3/2/2008 3 140 341 17.0 
 
3/3/2008 4 121 273 14.2 Liver biopsy: Bile duct loss 
3/4/2008 5 121 311 14.1 INR 1.21 
3/5/2008 6 136 418 12.2 Discharge 
4/9/2008 41 66 146 1.3 Asymptomatic 
5/8/2008 70 44 99 0.6 Normal 
8/11/2008 165 36 94 0.7 Normal 
Normal Values < 45 < 115 < 1.2   
Summary Table 
Feature Result 
Implicated Agent(s) Amoxicillin/Clavulanate 
Time to onset 21 days [12 days after stopping] 
Enzyme pattern Cholestatic (R ratio = 1.0) 
HEV testing Not tested 
HCV testing Anti-HCV neg  
Hospitalization Yes 
Prednisone No  
Ursodiol Yes 
Chronicity No 
Severity 3+ (Jaundiced, hospitalized) 
Causality 1 (Definite) 
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RUCAM 8 (Highly probable) 
Concomitant Medications 7 (Doxycycline, trazodone) 
Comment Resolved within 3 months 
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Clinical Summary: Case #   
Herbal Supplement with Artemesinin 
Bile Duct Loss 
 
A 66 year old Caucasian woman with asthma, who was taking many over-the-counter supplements and herbal 
preparations for asthma and general health, developed fatigue, dark urine and jaundice approximately 2 
months after starting a Chinese herbal preparation that contained artemesinin. She denied fever or rash. She 
had no history of liver disease, alcohol abuse or risk factors for viral hepatitis. She gave a history of multiple 
drug allergies and adverse reactions including jaundice after receipt of amoxicillin with clavulanic acid.  Her 
medical conditions included asthma, hypertension, gastroesophageal reflux and irritable bowel syndrome. Her 
other prescription medications included montelukast, hydroxyzine, theophylline, valsartan and pantoprazole. 
She was also taking multiple vitamins and minerals as well as herbal preparations including cat's claw, 
"betafood", cranberry, candida, chamomile, choline, Enzycore, flax oil, fibers, Gastrex, ginger, gymnema, 
"liverplex", milk thistle, pro-gest, quercetin, Ultra Clear, and whole food fiber, On presentation she was mildly 
jaundiced and blood tests showed a serum bilirubin of 2.6 mg/dL, ALT 663 U/L [14.7 times ULN], AST 184 U/L 
[5.3 times ULN] and alkaline phosphatase 281 U/L [2.2 times ULN].  The R ratio was 7.9 (hepatocellular). 
These values had been normal when tested one month previously. The INR was 1.0 and albumin 3.8 gm/dL. 
Tests for hepatitis A, B, C and E were negative as were ANA and SMA. A CT of the abdomen showed 
evidence of diverticulosis, but no abnormality of the liver or biliary tree. She was admitted to the hospital and 
the various herbal and dietary supplements were stopped. Serum bilirubin levels rose to a peak of 11.9 mg/dL 
three weeks after presentation. A liver biopsy was done on day 14 that showed changes of chronic cholestasis, 
moderate inflammation, marked bile duct injury and mild bile duct: among 20 portal areas, only 15 had 
identifiable bile ducts (bile duct fraction = 75%). She received no specific therapy for the liver injury and 
gradually improved. Jaundice cleared within 2 months, but her serum ALT and alkaline phosphatase levels 
remained elevated for more than a year. When she was seen 1 year after onset, she was asymptomatic but 
serum enzyme levels were still mildly elevated. On repeat testing after 2 years, the values were in the normal 
range. This case was scored as moderately severe (jaundice and hospitalization). A causality review group 
adjudicated the case as probably HDS-induced liver injury. The RUCAM score was 4 (possible). Because of 
the many single- and multi-ingredient dietary supplements that she was taking, it is difficult to assign causality 
to a specific herbal component.  
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Portal area with no evident duct (H&E, 400x) 
 
Portal area with several damaged ducts (arrows).  The periportal hepatocytes show pallor consistent with pseudoxanthomatous 
change. (H&E, 400x). 
Serial Laboratory Results 
Date 
Days from 
Onset 
ALT 
(U/L) 
Alk P 
(U/L) 
Bilirubin 
(mg/dL) 
Event 
3/5/2012 -67 
   
Herbal agents started 
4/19/2012 -22 39 87 0.2 Normal values 
5/5/2012 -6 
   
Onset of symptoms 
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Date 
Days from 
Onset 
ALT 
(U/L) 
Alk P 
(U/L) 
Bilirubin 
(mg/dL) 
Event 
5/9/2012 -2 
   
Herbal agents stopped 
5/11/2012 0 663 281 2.6 CT Scan: normal liver 
5/13/2012 2 531 274 3.6 MRCP normal biliary tree 
5/14/2012 3 473 278 4.3 
 
5/15/2012 4 405 280 4.8 
 
5/16/2012 5 332 262 5.1 Discharged  
5/21/2012 10 86 280 9.0 Liver biopsy: bile duct loss 
5/30/2012 19 63 275 7.7 
 
6/4/2012 24 45 247 11.9 
 
6/12/2012 32 86 254 7.2 
 
6/18/2012 38 134 259 4.9 
 
6/27/2012 47 149 262 3.2 
 
7/23/2012 73 101 243 0.9 
 
8/24/2012 105 112 357 0.6 
 
12/4/2012 207 53 176 0.8 6 month chronicity score = 1 
1/10/2013 244 64 235 0.4 Ultrasound normal 
3/25/2013 318 35 153 0.6 
 
7/17/2013 432 55 181 0.4 1 year chronicity score = 1 
3/26/2014 684 31 87 
 
Normal 
Normal Values < 40 < 130 < 1.2 
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Summary Table 
 
Feature Result 
Implicated Agent(s) Herbal agent with artemesinin 
Time to onset 67 days 
Enzyme pattern Hepatocellular (7.9), later cholestatic (<1.0) 
HEV testing Anti-HEV IgG pos, IgM neg 
HCV testing Anti-HCV neg, HCV RNA neg 
Hospitalization Yes 
Prednisone No 
Ursodiol Not mentioned 
Chronicity Yes, chronicity score 1 at 6 mo &1 year, 0 at 2 years  
Severity 3+ (Jaundiced, hospitalized) 
Causality 3 (probable)  
RUCAM 4 (possible) 
Concomittant medications Several multi-ingredient nutritional supplements 
Comment Mild duct loss and eventual recovery 
 
  . 
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